Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study

(2010) Kaoru Kubota et al.   Journal of Thoracic Oncology

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

(2009) Jie Ling et al.   ANTI-CANCER DRUGS

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Features of Gemcitabine-Related Severe Pulmonary Toxicity

(2009) Akihiro Tamiya et al.   PANCREAS

Interstitial Lung Disease in Japanese Patients with Lung Cancer

(2008) Shoji Kudoh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY